Ovarian cancer
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Who can joinWomen
Age18+ years
Kind of studyPhase 3: compared with usual treatment
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Where to go
9 hospitals in India taking patients for this trial.
Gujarat Cancer & Research InstituteAhmedabadDirections ↗
Saroj Gupta Cancer Center and Research Institute SGCC&RIKolkataDirections ↗
Tata Memorial HospitalMumbaiDirections ↗
National Cancer Institute NagpurNagpurDirections ↗
HCG Manavata Cancer CentreNashikDirections ↗
Ruby Hall ClinicPuneDirections ↗
HCG Cancer Centre VadodaraVadodaraDirections ↗
Mahamana Pandit Madan Mohan Malaviya Cancer CentreVaranasiDirections ↗
King George HospitalVisakhapatnamDirections ↗
Registry summary (technical)
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.
Sponsor: Daiichi Sankyo
NCT06819007 on ClinicalTrials.gov
Last updated on the registry 2 Jul 2026 · read by us 20 Oct 2026